Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
6
Bullish
4
Bearish
20
Neutral
6
Bullish
20
Bearish
16
Neutral
0
Bullish
16
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
422.15 | 4,449 Cr | 34.45 | 3.73 | 0.24 | 10.82 | 16.48 | 9.03 | ||
397.00 | 4,377 Cr | 93.79 | 15.21 | 0.17 | 16.22 | 14.47 | 9.27 | ||
856.70 | 4,359 Cr | 214.09 | 3.38 | 0.00 | 2.11 | 2.48 | 1.10 | ||
1211.20 | 4,195 Cr | -56.73 | 6.05 | 0.00 | -10.66 | -6.48 | -6.55 | ||
132.90 | 3,901 Cr | 28.34 | 2.17 | 0.75 | 7.65 | 10.29 | 5.32 | ||
387.95 | 3,890 Cr | 60.59 | 5.85 | 0.03 | 9.66 | 11.45 | 4.78 | ||
608.45 | 3,727 Cr | -694.00 | 4.46 | 0.00 | -2.93 | -2.42 | -0.57 | ||
| Median: 7 Co. | — | 422.15 | 4,195 Cr | 34.45 | 4.46 | 0.03 | 7.65 | 10.29 | 4.78 |
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Gujarat Themis Biosyn Limited is a Vapi-based pharmaceutical company specialized in fermentation‑based intermediates and APIs, historically known for rifamycin intermediates and recently commissioned a multi-purpose API plant to forward‑integrate its value chain and target domestic and export markets.
The company reported Q3 FY26 revenue of Rs. 43.37 crore (up ~9.7% YoY) with an exceptionally high EBITDA margin of 49.1% in the quarter, reflecting tight cost optimization and volume growth despite higher manpower and depreciation costs during capex ramp-up.
GTBL has completed significant capex: a new fermentation facility and a commercial API unit (operations from 6 May 2025), and its balance sheet shows PPE rising sharply and non‑current borrowings increasing, underlining an active investment phase to expand capacity and product mix.
Management disclosed R&D spend of about 3% of revenue for the nine months, ongoing validation batches for API blocks, and is establishing a new R&D center; the company targets forward integration and export expansion while also commissioning an 18.5 MW captive wind‑solar hybrid plant to reduce power costs and carbon footprint.
Pharmaceuticals & Biotechnology
Pharmaceuticals
4,377 Cr
High Risk
93.8
34.1
24.8
15.2
479.45
225.75
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Gujarat Themis Biosyn Ltd (GUJTHEM) is currently trading at 385.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gujarat Themis Biosyn Limited is a Vapi-based pharmaceutical company specialized in fermentation‑based intermediates and APIs, historically known for rifamycin intermediates and recently commissioned a multi-purpose API plant to forward‑integrate its value chain and target domestic and export markets. The company reported Q3 FY26 revenue of Rs. 43.37 crore (up ~9.7% YoY) with an exceptionally high EBITDA margin of 49.1% in the quarter, reflecting tight cost optimization and volume growth despite higher manpower and depreciation costs during capex ramp-up. GTBL has completed significant capex: a new fermentation facility and a commercial API unit (operations from 6 May 2025), and its balance sheet shows PPE rising sharply and non‑current borrowings increasing, underlining an active investment phase to expand capacity and product mix. Management disclosed R&D spend of about 3% of revenue for the nine months, ongoing validation batches for API blocks, and is establishing a new R&D center; the company targets forward integration and export expansion while also commissioning an 18.5 MW captive wind‑solar hybrid plant to reduce power costs and carbon footprint.
Over the past 52 weeks, Gujarat Themis Biosyn Ltd has traded between a low of ₹225.75 and a high of ₹479.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gujarat Themis Biosyn Ltd has a market capitalization of approximately 4,377.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gujarat Themis Biosyn Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 93.79 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,377.13 Cr, Gujarat Themis Biosyn Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gujarat Themis Biosyn Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gujarat Themis Biosyn Ltd is 93.79. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board approved raising up to ₹1,000 crore through a Qualified Institutions Placement (QIP) and a preferential issue of equity shares to non-promoters, subject to approvals.
It has approved raising up to ₹1,000 crore via a Qualified Institutions Placement (QIP) under SEBI ICDR Regulations, with additional funds potentially via a preferential issue to non-promoters.
It reported a net profit (PAT) of ₹46.68 crore for the year ended March 31, 2026.
GTBL has signed a definitive agreement to acquire 100% equity in MicroBiopharm Japan Co., Ltd. through its Japan vehicle/SPV, subject to approvals.
QIP Postal Ballot
Gujarat Themis Biosyn Ltd. has issued a postal ballot notice seeking shareholder approval to empower the Board to issue equity/equity‑linked securities up to Rs.1,000 crore via Qualified Institutions Placement; remote e‑voting: 9 Jun–8 Jul 2026.
Capital raise
Board approved proposal to raise up to Rs.1,000 crore through Qualified Institutions Placement and to pursue preferential issue to non‑promoters, subject to shareholder and regulatory approvals; details to be decided by committee.
Equity Fundraising
Board on 6 June 2026 approved raising up to Rs.1,000 crore through Qualified Institutions Placement and/or other permissible modes, including preferential issue to non‑promoters, in tranches subject to shareholder and regulatory approvals.
Postal Ballot Result
Gujarat Themis Biosyn shareholders passed a special resolution to increase borrowing limits under Section 180(1)(c) and permit creation of mortgages/charges via postal ballot; scrutinizer's report dated 4 Jun 2026; promoters cast 76,557,741 e‑votes (100% in favour).
Postal Ballot Result
Shareholders of Gujarat Themis Biosyn passed special resolutions (Scrutinizer's Report dated 4 Jun 2026) to increase borrowing limits under Section 180(1)(c) and permit creation of mortgages/charges; promoter e-voting polled 99.1448% with all polled votes in favour (76,557,741).
Postal Ballot Outcome
Gujarat Themis Biosyn Ltd shareholders approved special resolutions via postal ballot (Scrutinizers' report dated 4 Jun 2026) to increase borrowing limits under Section 180(1)(c) and to create mortgages/charges; results posted online.
